Paul Harper
Chairman bij Sareum Ltd.
Vermogen: 19 059 $ op 29-02-2024
Oorsprong van het eerstegraads netwerk van Paul Harper
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 18 | |
Public Company | Miscellaneous Commercial Services | 11 | |
Angel Biotechnology Holdings Plc
Angel Biotechnology Holdings Plc BiotechnologyHealth Technology Angel Biotechnology Holdings Plc operated as a contract bio-manufacturing company that offers process development, pre-GMP and cGMP manufacturing services. The company specialized in offering the cGMP manufacture of advanced biologics including stem cells, cell therapies, recombinant proteins, antibodies and viruses for clinical trial use and commercial sale. It also provided development and manufacturing support for production of biologics working from laboratory scale to development of a robust manufacturing process. Angel Biotechnology was founded on December 7, 2000 and was headquartered in Edinburgh, the United Kingdom.
8
| Extinct | Biotechnology | 8 |
Sareum Ltd.
Sareum Ltd. Drugstore ChainsRetail Trade Sareum Ltd. provides drug discovery services for treatment of cancer. The company develops robust pipeline of novel small molecule cancer drug candidates for partnering with pharmaceutical companies. Sareum is headquartered in Cambridge, UK
2
| Subsidiary | Drugstore Chains | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Paul Harper via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Athena Neurosciences LLC
Athena Neurosciences LLC Miscellaneous Commercial ServicesCommercial Services Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Medical Distributors | Founder Chief Tech/Sci/R&D Officer | |
SAREUM HOLDINGS PLC | Miscellaneous | Chairman Director/Board Member | |
TIGENIX NV | Medical Specialties | Director of Finance/CFO | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
Circassia Ltd.
Circassia Ltd. Pharmaceuticals: OtherHealth Technology Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Imperial College London | College/University | Undergraduate Degree Graduate Degree Masters Business Admin Undergraduate Degree | |
Excalibur Fund Managers Ltd.
Excalibur Fund Managers Ltd. Investment ManagersFinance Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom. | Investment Managers | Founder Founder | |
University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
GlaxoWellcome /Pharmocology Unit/ | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
City Capital Corp. Ltd.
City Capital Corp. Ltd. Investment Banks/BrokersFinance City Capital Corp. Ltd. provides brokerage services. The private company is based in London, UK. and has subsidiaries in Bermuda. The British company was founded in 2002. David C. Meacher has been the CEO of the company since 2003. | Investment Banks/Brokers | Analyst-Equity | |
Simbec Research Ltd.
Simbec Research Ltd. Miscellaneous Commercial ServicesCommercial Services Simbec Research Ltd. provides clinical research service to pharmaceutical and biotechnology industries. It conducts drug trails for allergy, anti-infectives, cardiovascular, gastrointestinal, anti-inflammatory, oncology and respiratory. The firm also offers consultancy services, preparation of marketing authorization applications, and clinical trial applications. The company was founded in 1976 and is headquartered in Merthyr Tydfil, the United Kingdom. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
University of London | College/University | Doctorate Degree Graduate Degree | |
University of Strathclyde | College/University | Undergraduate Degree Doctorate Degree | |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member | |
The University of Nottingham | College/University | Undergraduate Degree Doctorate Degree | |
Equity Development Ltd.
Equity Development Ltd. Investment ManagersFinance Equity Development Ltd. is an investment research firm headquartered in London, UK. The firm was founded by Brian Basham in 1997 and is a subsidiary of Equity Holdings Ltd., which is owned by Bashco Ltd. Equity Development provides investors of all types with freely available equity research and direct access to quoted companies’ management. | Investment Managers | Analyst-Equity | |
University of Bocconi | College/University | Doctorate Degree | |
Edison Investment Research Ltd.
Edison Investment Research Ltd. Investment ManagersFinance Edison Investment Research Ltd. (Edison) is an investment research, investor relations and consulting firm headquartered in London, UK. The firm was founded by Stephen Rogers and Fraser Thorne in 2003. They are a subsidiary of Edison Global Ltd. Edison provides investment research to international investors, advisors and stakeholders. | Investment Managers | Analyst-Equity | |
London Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
UK Stem Cell Foundation | Investment Trusts/Mutual Funds | Founder Founder | |
King's College London | College/University | Corporate Officer/Principal Doctorate Degree | |
BANCO SANTANDER, S.A. | Major Banks | Corporate Officer/Principal | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director of Finance/CFO | |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Simbec-Orion Group Ltd.
Simbec-Orion Group Ltd. Pharmaceuticals: MajorHealth Technology Simbec-Orion Group Ltd. provides contract research services for rare and orphan conditions. The firm offers services for oncology, orphan diseases, respiratory, dermatology, infectious vaccines and diseases. The company was founded in 2014 and is headquartered in Pentrebach, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
NUFORMIX PLC | Biotechnology | Comptroller/Controller/Auditor | |
Proactive Investors Ltd.
Proactive Investors Ltd. Investment ManagersFinance Proactive Investors Ltd. is a financial media portal that connects companies and investors. The company is based in London, UK, and has subsidiaries in the United States. The British company provides breaking news, commentary, and analysis on hundreds of listed companies and pre-IPO businesses globally, 24/7. The company offers in-depth comment, analysis, press releases, and share price data on small to large capitalized companies. Proactive is one of the fastest-growing financial media portals in the world, leading in up-to-the-minute, multi-media news provision, events organization, and investor research. The company was founded in 2006 by Craig Ribton, who has been the CEO since 2006. | Investment Managers | Analyst-Equity | |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Biotechnology | Director of Finance/CFO | |
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC | Chief Tech/Sci/R&D Officer |
Statistieken
Internationaal
Verenigd Koninkrijk | 28 |
Verenigde Staten | 7 |
Spanje | 4 |
België | 3 |
Ierland | 2 |
Sectoraal
Health Technology | 18 |
Consumer Services | 10 |
Finance | 8 |
Commercial Services | 6 |
Miscellaneous | 3 |
Operationeel
Director/Board Member | 201 |
Corporate Officer/Principal | 75 |
Chairman | 62 |
Independent Dir/Board Member | 35 |
Founder | 34 |
Sterkste connecties
Insiders | |
---|---|
Christopher Evans | 62 |
Simon Cartmell | 39 |
Trevor Jones | 36 |
Stephen Parker | 32 |
John Berriman | 24 |
Bryan Geoffrey Morton | 22 |
Gavin David Clark | 22 |
Timothy Corn | 20 |
Michael Owen | 20 |
Mark James Docherty | 14 |
Olav Hellebø | 13 |
Claudia D'Augusta | 12 |
Martin Gouldstone | 12 |
Mark Philip Chadwick | 9 |
Stewart White | 8 |
- Beurs
- Insiders
- Paul Harper
- Bedrijfsconnecties